The U.S. Department of Health and Human Services plans to revise labeling requirements for testosterone therapy medications to address safety concerns related to prostate cancer risk and treatment of hypogonadism. The updated labels are intended to provide clearer guidance to healthcare providers and patients about the benefits and risks associated with testosterone replacement therapy. This action reflects ongoing regulatory efforts to ensure medication safety information remains current with medical evidence.
Stress, Anxiety & Mental Wellness · Jun 23, 2026 · 1 day ago
HHS to Update Testosterone Therapy Labels for Cancer and Hypogonadism
Read the full story at healthline.com →
This summary was prepared by the HealthyFreePress editorial desk; the underlying reporting belongs to the linked publisher. Nothing here is medical advice — see our Medical Disclaimer and Editorial Policy.